Effect of Pluronic P85 on ATPase Activity of Drug Efflux Transporters

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2005 Jan 15

PMID 15648254

Citations 41

Authors

Elena V Batrakova

Shu Li

Yili Li

Valery Yu Alakhov

Alexander V Kabanov

Affiliations

Soon will be listed here.

Abstract

Purpose: Pluronic block copolymers are potent sensitizers of multi-drug resistant (MDR) cancer cells. The sensitization effect by Pluronics is a result of two processes acting in concert: i) intracellular ATP depletion, and ii) inhibition of ATPase activity of drug efflux proteins. This work characterizes effects of Pluronic P85 on ATPase activities of Pgp, MRP1, and MRP2 drug efflux transport proteins and interaction of these proteins with their substrates, vinblastine, and leucotriene C4.

Methods: Using membranes overexpressing Pgp, MRP1, and MRP2, the current study evaluates effects of Pluronic P85 (P85) on the kinetic parameters (Vmax, Km, Vmax/Km) of ATP hydrolysis by these ATPases.

Results: The decreases in the maximal reaction rates (Vmax) and increases in apparent Michaelis constants (Km) for these transporters in the presence of various concentrations of P85 were observed. The mechanism of these effects may involve i) conformational changes of the transporter due to membrane fluidization and/or ii) nonspecific steric hindrance of the drug-binding sites by P85 chains embedded into cellular membranes. The extent of these alterations was increased in the row MRP1 < MRP2 << Pgp.

Conclusions: These data suggest that there are unifying pathways for the inhibition of Pgp and MRPs by the block copolymer. However, the effect of P85 on Pgp ATPase activity is considerably greater compared with the effects on MRP1 and MRP2 ATPases. This may be a reason for greater inhibitory effects of Pluronic in Pgp- compared with MRP-overexpressing cells.

Citing Articles

Third-Generation Solid Dispersion Through Lyophilization Enhanced Oral Bioavailability of Resveratrol.

Almeida H, Ferreira B, Fernandes-Lopes C, Araujo F, Bonifacio M, Vasconcelos T ACS Pharmacol Transl Sci. 2024; 7(3):888-898.

PMID: 38481698 PMC: 10928883. DOI: 10.1021/acsptsci.4c00029.

An Oral 3D Printed PLGA-Tocopherol PEG Succinate Nanocomposite Hydrogel for High-Dose Methotrexate Delivery in Maintenance Chemotherapy.

Kondiah P, Rantso T, Makhathini S, Mdanda S, Choonara Y Biomedicines. 2022; 10(7).

PMID: 35884775 PMC: 9313284. DOI: 10.3390/biomedicines10071470.

Emerging Applications of Nanotechnology in Healthcare Systems: Grand Challenges and Perspectives.

Anjum S, Ishaque S, Fatima H, Farooq W, Hano C, Abbasi B Pharmaceuticals (Basel). 2021; 14(8).

PMID: 34451803 PMC: 8401281. DOI: 10.3390/ph14080707.

Investigation to Explain Bioequivalence Failure in Pravastatin Immediate-Release Products.

Ruiz-Picazo A, Colon-Useche S, Perez-Amoros B, Gonzalez-Alvarez M, Molina-Martinez I, Gonzalez-Alvarez I Pharmaceutics. 2019; 11(12).

PMID: 31835294 PMC: 6956045. DOI: 10.3390/pharmaceutics11120663.

Eradication of cancer stem cells in triple negative breast cancer using doxorubicin/pluronic polymeric micelles.

Zhao Y, Alakhova D, Zhao X, Band V, Batrakova E, Kabanov A Nanomedicine. 2019; 24:102124.

PMID: 31756533 PMC: 9038110. DOI: 10.1016/j.nano.2019.102124.

References

Choi C, Sun K, An C, Yoo J, Hahm K, Lee I . Reversal of P-glycoprotein-mediated multidrug resistance by 5,6,7,3',4'-pentamethoxyflavone (Sinensetin). Biochem Biophys Res Commun. 2002; 295(4):832-40. DOI: 10.1016/s0006-291x(02)00755-6. View

Landwojtowicz E, Nervi P, Seelig A . Real-time monitoring of P-glycoprotein activation in living cells. Biochemistry. 2002; 41(25):8050-7. DOI: 10.1021/bi025720s. View

Batrakova E, Li S, Alakhov V, Miller D, Kabanov A . Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther. 2003; 304(2):845-54. DOI: 10.1124/jpet.102.043307. View

Bogman K, Erne-Brand F, Alsenz J, Drewe J . The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J Pharm Sci. 2003; 92(6):1250-61. DOI: 10.1002/jps.10395. View

Batrakova E, Li S, Alakhov V, Elmquist W, Miller D, Kabanov A . Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharm Res. 2003; 20(10):1581-90. PMC: 3070744. DOI: 10.1023/a:1026179132599. View

Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D . Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer. 2004; 90(11):2085-91. PMC: 2409484. DOI: 10.1038/sj.bjc.6601856. View

Sarkadi B, Price E, Boucher R, Germann U, Scarborough G . Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem. 1992; 267(7):4854-8. View

Higgins C . ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992; 8:67-113. DOI: 10.1146/annurev.cb.08.110192.000435. View

Hyafil F, Vergely C, du Vignaud P, Grand-Perret T . In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993; 53(19):4595-602. View

10.

Leyland-Jones B, Dalton W, Fisher G, Sikic B . Reversal of multidrug resistance to cancer chemotherapy. Cancer. 1993; 72(11 Suppl):3484-8. DOI: 10.1002/1097-0142(19931201)72:11+<3484::aid-cncr2820721615>3.0.co;2-l. View

11.

Drueckes P, Schinzel R, Palm D . Photometric microtiter assay of inorganic phosphate in the presence of acid-labile organic phosphates. Anal Biochem. 1995; 230(1):173-7. DOI: 10.1006/abio.1995.1453. View

12.

Hwang M, Ahn C, Pine P, Yin J, Hrycyna C, Licht T . Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells. Int J Cancer. 1996; 65(3):389-97. DOI: 10.1002/(SICI)1097-0215(19960126)65:3<389::AID-IJC19>3.0.CO;2-5. View

13.

Loe D, Almquist K, Deeley R, Cole S . Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem. 1996; 271(16):9675-82. DOI: 10.1074/jbc.271.16.9675. View

14.

Alakhov VYu , Moskaleva EYu , Batrakova E, Kabanov A . Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug Chem. 1996; 7(2):209-16. DOI: 10.1021/bc950093n. View

15.

Venne A, Li S, Mandeville R, Kabanov A, Alakhov V . Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 1996; 56(16):3626-9. View

16.

Taguchi Y, Yoshida A, Takada Y, Komano T, Ueda K . Anti-cancer drugs and glutathione stimulate vanadate-induced trapping of nucleotide in multidrug resistance-associated protein (MRP). FEBS Lett. 1997; 401(1):11-4. DOI: 10.1016/s0014-5793(96)01421-4. View

17.

Draper M, Martell R, Levy S . Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br J Cancer. 1997; 75(6):810-5. PMC: 2063393. DOI: 10.1038/bjc.1997.145. View

18.

Stein W . Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev. 1997; 77(2):545-90. DOI: 10.1152/physrev.1997.77.2.545. View

19.

Chan H, Lu Y, Grogan T, Haddad G, Hipfner D, Cole S . Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res. 1997; 57(12):2325-30. View

20.

Litman T, Nielsen D, Skovsgaard T, Zeuthen T, Stein W . ATPase activity of P-glycoprotein related to emergence of drug resistance in Ehrlich ascites tumor cell lines. Biochim Biophys Acta. 1997; 1361(2):147-58. DOI: 10.1016/s0925-4439(97)00025-2. View